AIM Vaccine submits mRNA RSV vaccine for FDA clinical trials

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S. Food and Drug Administration (FDA).

New “pseudo cell” formulation could revolutionize treatment of vitreoretinal diseases

Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences and Beijing Chaoyang Hospital have developed a new “pseudo cell” formulation

October 24, 2023

Novel biochip diagnoses deadly brain cancer in under an hour

Researchers at the University of Notre Dame have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less

August 28, 2024

Top HHS official doesn’t think the election will impact AI rules

The federal government’s top official in charge of regulating artificial intelligence in health care said the upcoming presidential election won’t impact regulations, despite fears from

October 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.